|
|
|
|
[123I](-CIT SPECT seems to be a useful tool to investigate the progression of dopaminergic degeneration in Parkinson's disease and may provide an objective method of measuring the effectiveness of neuroprotective treatments. Short term trea tment with a D2 agonist does not have a significant influence on [123I](-CIT SPECT binding to dopamine transporters. If the latter finding is replicated in larger groups of patients, it supports the suitability of [123I](-CIT SPECT for examining the prog ression of neurodegeneration in patients being treated with D2 receptor agonists. |
|